Abubakar Sadiq Abdullahi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abubakar Sadiq Abdullahi has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Adebowale Olufemi Adeluola
1 shared publication- Adebowale Olufemi Adeluola
Department of Pharmaceutical Microbiology & Biotechnology, Faculty of Pharmacy, University of Lagos College of Medicine Campus, Idi-araba, Lagos, Nigeria
1 shared publication - Albisto Adriano
Biodiversity and Medicinal Chemistry Group, School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP), Department of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
1 shared publication - Alice Rhelly Veloso Carvalho
Biodiversity and Medicinal Chemistry Group, School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP) University of São Paulo Ribeirão Preto São Paulo Brazil
1 shared publication - Bakary N’TJi Diallo
University of Science Techniques and Technologies of Bamako (USTTB), Bamako, Mali
1 shared publication - Boris Davy Bekono
Department of Physics, Ecole Normale Supérieure, University of Yaoundé 1, Yaoundé, Cameroon
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 18 (1) , 122
Computational applications in secondary metabolite discovery (CAiSMD) 2026: focus on secondary metabolites towards drug discovery
- 24 August 2026
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 18 (1) , 122
Open AccessComputational applications in secondary metabolite discovery (CAiSMD) 2026: focus on secondary metabolites towards drug discovery
- Open Access
- 26 June 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1)
Experimental evaluation of levofloxacin efficacy against multidrug-resistant bacterial isolates at the Lagos University Teaching Hospital, Nigeria
Background: Key mechanisms contributing to antibacterial resistance include efflux pump overexpression and enzymatic drug inactivation. Levofloxacin, a widely prescribed fluoroquinolone, demonstrates potent activity against Gram-positive pathogens, such as Streptococcus pneumoniae , and Gram-negative pathogens, such as Pseudomonas aeruginosa . However, the increasing prevalence of multidrug resistance (MDR) continues to compromise its clinical utility. To date, there is a paucity of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) data of levofloxacin against previously characterised MDR isolates with defined resistance mechanisms. Methods: Using agar well diffusion and agar dilution techniques, this experimental study evaluated the antibacterial activity, MIC, and MBC of levofloxacin against 20 bacterial isolates, comprising 18 previously characterised clinical MDR isolates and 2 American Type Culture Collection (ATCC) reference strains. Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923) served as drug-susceptible quality control strains. Data were expressed as mean ± standard deviation (SD), and p < 0.05 was considered statistically significant. Results: Three of eight Klebsiella pneumoniae isolates were non-susceptible to levofloxacin across four tested concentrations ranging from 6.25 to 50 µg/mL. One Staphylococcus aureus isolate (ES 44), previously characterised as multidrug resistant, exhibited high-level resistance (MIC: 8 µg/mL). MIC values ranged from 0.0625 to 8 µg/mL for Gram-positive and 0.015625–1 µg/mL for Gram-negative organisms. MBC values ranged from 0.125 to 8 µg/mL for Gram-positive and 0.015625–8 µg/mL for Gram-negative isolates. Micrococcus spp. exhibited high susceptibility (inhibition zone at 50 µg/mL: 37.33 ± 0.58 mm; MIC: 0.125 µg/mL). Overall, levofloxacin exhibited significantly higher inhibitory activity against Gram-negative (72.73%) than Gram-positive isolates (55.56%) ( p < 0.05). Conclusion: This study demonstrates variability in levofloxacin MIC and MBC values among previously characterised MDR bacterial isolates at Lagos University Teaching Hospital. While levofloxacin retains activity against several pathogens, reduced susceptibility among some MDR isolates highlights the need for informed prescribing, continuous resistance surveillance, and strengthened antimicrobial stewardship efforts in Nigeria.
- 26 June 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1)
Open AccessExperimental evaluation of levofloxacin efficacy against multidrug-resistant bacterial isolates at the Lagos University Teaching Hospital, Nigeria
Background: Key mechanisms contributing to antibacterial resistance include efflux pump overexpression and enzymatic drug inactivation. Levofloxacin, a widely prescribed fluoroquinolone, demonstrates potent activity against Gram-positive pathogens, such as Streptococcus pneumoniae , and Gram-negative pathogens, such as Pseudomonas aeruginosa . However, the increasing prevalence of multidrug resistance (MDR) continues to compromise its clinical utility. To date, there is a paucity of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) data of levofloxacin against previously characterised MDR isolates with defined resistance mechanisms. Methods: Using agar well diffusion and agar dilution techniques, this experimental study evaluated the antibacterial activity, MIC, and MBC of levofloxacin against 20 bacterial isolates, comprising 18 previously characterised clinical MDR isolates and 2 American Type Culture Collection (ATCC) reference strains. Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923) served as drug-susceptible quality control strains. Data were expressed as mean ± standard deviation (SD), and p < 0.05 was considered statistically significant. Results: Three of eight Klebsiella pneumoniae isolates were non-susceptible to levofloxacin across four tested concentrations ranging from 6.25 to 50 µg/mL. One Staphylococcus aureus isolate (ES 44), previously characterised as multidrug resistant, exhibited high-level resistance (MIC: 8 µg/mL). MIC values ranged from 0.0625 to 8 µg/mL for Gram-positive and 0.015625–1 µg/mL for Gram-negative organisms. MBC values ranged from 0.125 to 8 µg/mL for Gram-positive and 0.015625–8 µg/mL for Gram-negative isolates. Micrococcus spp. exhibited high susceptibility (inhibition zone at 50 µg/mL: 37.33 ± 0.58 mm; MIC: 0.125 µg/mL). Overall, levofloxacin exhibited significantly higher inhibitory activity against Gram-negative (72.73%) than Gram-positive isolates (55.56%) ( p < 0.05). Conclusion: This study demonstrates variability in levofloxacin MIC and MBC values among previously characterised MDR bacterial isolates at Lagos University Teaching Hospital. While levofloxacin retains activity against several pathogens, reduced susceptibility among some MDR isolates highlights the need for informed prescribing, continuous resistance surveillance, and strengthened antimicrobial stewardship efforts in Nigeria.
- Open Access
- 24 February 2026
- Published by Springer Nature in Research Square
UNLOCKING SAFE REMEDIES: Preclinical Toxicological Evaluation of the Hydroethanolic Extract of Spondias mombin in Rodents
Background : Toxicity accounts for nearly one-third of candidate drug attrition, underscoring the need for robust preclinical toxicological evaluation early in the drug development pipeline. To the best of our knowledge, this is the first comprehensive toxicological profiling of Spondias mombin hydroethanolic leaf extract in rodent models in Nigeria. Traditionally used for the treatment of dysentery, gonorrhea, wounds, and anemia, S. mombin hydroethanolic extract warrants systematic evaluation to support its safe therapeutic use and guide the optimization of lead compounds. Methods : Acute toxicity was assessed in mice using a limit test following a single oral dose and a 14-day observation period. Subacute and subchronic toxicity were evaluated in female Wistar rats (n = 6/group and n=10/group) administered 40, 200, or 1000 mg/kg/day of extract for 28 and 60 days, respectively. A control group received distilled water. Hematological and biochemical analyses were conducted post-treatment before humane euthanasia. Results : No mortality or observable signs of toxicity were recorded at doses up to 2000 mg/kg. The extract significantly reduced white blood cell count, absolute lymphocytes, and total bilirubin (WBC: 5.60 × 10³/µL vs. 9.35 × 10³/µL; lymphocytes: 2.08 × 10³/µL vs. 4.28 × 10³/µL; bilirubin: 1.99 µmol/L vs. 2.39 µmol/L). S. mombin extract also exhibited dose-dependent increases in red blood cell and hemoglobin counts, alongside reductions in AST, ALT, and ALP levels in the subacute phase. In the subchronic study, S. mombin significantly reduced total cholesterol (40 mg/kg: 1.96 mmol/L vs. control: 2.85 mmol/L) and bilirubin (1000 mg/kg: 10.69 µmol/L vs. control: 22.58 µmol/L). Conclusion : The validated safety profile of S. mombin hydroethanolic leaf extract supports its continued ethnomedicinal use and highlights its promise as a candidate for further pharmacological development—particularly as a potential hematinic, anti-infective, and hepatoprotective agent.
- 24 February 2026
- Published by Springer Nature in Research Square
Open AccessUNLOCKING SAFE REMEDIES: Preclinical Toxicological Evaluation of the Hydroethanolic Extract of Spondias mombin in Rodents
Background : Toxicity accounts for nearly one-third of candidate drug attrition, underscoring the need for robust preclinical toxicological evaluation early in the drug development pipeline. To the best of our knowledge, this is the first comprehensive toxicological profiling of Spondias mombin hydroethanolic leaf extract in rodent models in Nigeria. Traditionally used for the treatment of dysentery, gonorrhea, wounds, and anemia, S. mombin hydroethanolic extract warrants systematic evaluation to support its safe therapeutic use and guide the optimization of lead compounds. Methods : Acute toxicity was assessed in mice using a limit test following a single oral dose and a 14-day observation period. Subacute and subchronic toxicity were evaluated in female Wistar rats (n = 6/group and n=10/group) administered 40, 200, or 1000 mg/kg/day of extract for 28 and 60 days, respectively. A control group received distilled water. Hematological and biochemical analyses were conducted post-treatment before humane euthanasia. Results : No mortality or observable signs of toxicity were recorded at doses up to 2000 mg/kg. The extract significantly reduced white blood cell count, absolute lymphocytes, and total bilirubin (WBC: 5.60 × 10³/µL vs. 9.35 × 10³/µL; lymphocytes: 2.08 × 10³/µL vs. 4.28 × 10³/µL; bilirubin: 1.99 µmol/L vs. 2.39 µmol/L). S. mombin extract also exhibited dose-dependent increases in red blood cell and hemoglobin counts, alongside reductions in AST, ALT, and ALP levels in the subacute phase. In the subchronic study, S. mombin significantly reduced total cholesterol (40 mg/kg: 1.96 mmol/L vs. control: 2.85 mmol/L) and bilirubin (1000 mg/kg: 10.69 µmol/L vs. control: 22.58 µmol/L). Conclusion : The validated safety profile of S. mombin hydroethanolic leaf extract supports its continued ethnomedicinal use and highlights its promise as a candidate for further pharmacological development—particularly as a potential hematinic, anti-infective, and hepatoprotective agent.